Orofacial Crohn's disease: An oral enigma

Acta Dermatovenerologica Croatica

Volumn 17, Issue 4, 2009, Pages 289-300

  Fatahzadeh, Mahnaz ^a   Schwartz, Robert A ^a   Kapila, Rajendra ^a   Rochford, Christopher ^a  

^a RUTGERS SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

Crohn's disease; Oral disease; Pyoderma gangrenosum

Indexed keywords

CORTICOSTEROID; MESALAZINE; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; VANCOMYCIN;

ABSCESS; ADULT; ANEMIA; ARTICLE; CASE REPORT; CELLULITIS; CERVICAL LYMPHADENOPATHY; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CROHN DISEASE; ERYTHROCYTE TRANSFUSION; FACE EDEMA; FEVER; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MALE; MOUTH DISEASE; MOUTH ULCER; ORAL BIOPSY; OROFACIAL CROHN DISEASE; PATIENT COMPLIANCE; PUSTULE; RECTUM HEMORRHAGE; TRISMUS;

CROHN DISEASE; FACIAL DERMATOSES; HUMANS; MALE; MIDDLE AGED; MOUTH DISEASES;

EID: 75149163890     PISSN: 1330027X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (116)

1. Hanauer SB, Sandborn W, Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2001;96:635-43.
2. Kornbluth A, Sacher DB. Ulcerative Colitis Practice Guidelines in Adults. Am J Gastroenterol 2004;99:1371-85.
3. Harty S, Fleming P, Rowland M, Crushell E, McDermott M, Drumm B, et al. A prospective study of the oral manifestations of Crohn's disease. Clin Gastroenterol Hepatol 2005;3:886-91.
4. Crohn BB, Ginzbur L, Oppenheimer GD. Regional ileitis. JAMA 1932;99:1323-9.
5. Karlinger K, Gyorke T, Mako E, Mester A, Tarjan Z. The epidemiology and the pathogenesis of inflammatory bowel disease. Eur J Radiol 2000;35:154-67.
6. Jacobsen BA, Fallingborg J, Rasmussen HH, Nielsen KR, Drewes AM, Puho E, et al. Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978-2002. Eur J Gastroenterol Hepatol 2006;18:601-6.
7. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347: 417-29.
8. Palamarus I, El-Jabbour J, Pietropaolo N, Thompson P, Mann S, Robles W, et al. Metastatic Crohn's disease: a review. J Eur Acad Dermatol Venereol 2008;22:1033-43.
9. Basu MK, Asquith P, Thompson RA, Cooke WT. Oral manifestations of Crohn's disease. Gut 1975;16:249-54.
10. Yamamoto-Furusho JK, Korzenik JR. Crohn's disease: innate immunodeficiency? World J Gastroenterol 2006;12:6751-5.
11. Ricci C, Lanzarotto F, Lanzini A. The multidisciplinary team for management of inflammatory bowel diseases. Dig Liver Dis 2008;40 Suppl 2:S285-8.
12. Greenstein AJ, Janowitz HD, Sachar DB. The extraintestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine 1976;55:401-12.
13. Rankin GB, Watts HD, Melnyk CS, Kelley ML. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 1979;77:914-20.
14. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001;96:1116-22.
15. Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005;11:7227-36.
16. Burgdorf W. Cutaneous manifestations of Crohn's disease. J Am Acad Dermatol 1981;5:689-95.
17. Schrodt BJ, Callen JP. Metastatic Crohn's disease presenting as chronic perivulvar and peri rectal ulcerations in an adolescent patient. Pediatrics 1999:103:500-2.
18. Plauth M, Jenss H, Meyle J. Oral manifestations of Crohn's disease. An analysis of 79 cases. J Clin Gastroenterol 1991;13:29-37.
19. Ploysangam T, Heubi JE, Eisen D, Balistreri WF, Lucky AW. Cutaneous Crohn's disease in children. J Am Acad Dermatol 1997;36:697-704.
20. McCallum DI, Kinmont PD. Dermatological manifestations of Crohn's disease. Br J Dermatol 1968;80:1-8.
21. Fenniche D, Mokni M, Haouet S, Ben Osman A. Vulvar Crohn disease: 3 cases. Ann Dermatol Venereol 1997;124:629-32.
22. Biancone L, Geoboes K, Spagnoli LG, Del Vecchio Blanco G, Monteleone I, Vavassori P, et al. Metastatic Crohn's disease of the forehead. Inflamm Bowel Dis 2002;8:101-5.
23. Schwab RA, Giblin WJ, James WD, Lupton GP. Multiple cutaneous ulcerations: cutaneous ulcerations in Crohn's disease (metastatic Crohn's disease). Arch Dermatol 1993;129:1607-8.
24. Vaz A, Kramer K, Kalish RA. Sweet's syndrome in association with Crohn's disease. Postgrad Med J 2000;76:713-4.
25. Farhi D, Cosnes J, Zizi N, Chosidow O, Seksik P, Beaugerie L, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore) 2008; 87:381-93.
26. Guest GD, Fink RLW. Metastatic Crohn's disease: case report of an unusual variant and review of the literature. Dis Colon Rectum 2000;43:1764-6.
27. Mahadevan U, Sandborn WJ. Infliximab for the treatment of orofacial Crohn's disease. Inflamm Bowel Dis 2001;7:38-42.
28. Chen W, Blume-Peytavi U, Goerdt S, Orfanos C. Metastatic Crohn's disease of the face. J Am Acad Dermatol 1996;35:986-8.
29. Peltz S, Vestey JP, Ferguson A, Hunter JA, McLaren K. Disseminated metastatic cutaneous Crohn's disease. Clin Exp Dermatol 1993;18:55-9.
30. Sangueza OP, Davis LS, Gourdin FW. Metastatic Crohn's disease. South Med J 1997;90:897-900.
31. Graham DB, Jager DL, Borum ML. Metastatic Crohn's disease of the face. Dig Dis Sci 2006;51:2062-3.
32. Kolansky G, Kimbrough-Green C, Dubin HV. Metastatic Crohn's disease of the face: an uncommon presentation. Arch Dermatol 1993;129:1348-9.
33. Mountain JC. Cutaneous ulceration in Crohn's disease. Gut 1970;11:18-26.
34. Singh B, Mortensen NJ, Jewell DP, George B. Perianal Crohn's disease. Br J Surg 2004;91:801-14.
35. Baker WN, Milton-Thompson GJ. The anal lesion as the sole presenting symptom of intestinal Crohn's disease. Gut 1971;12:865.
36. van de Scheur MR, van der Waal RI, van der Waal I, Stoof TJ, van Deventer SJ. Ano-genital granulomatosis: the counterpart of orofacial granulomatosis. J Eur Acad Dermatol Venereol 2003;17:184-9.
37. Poon KS, Gilks CB, Masterson JS. Metastatic Crohn's disease involving the genitalia. J Urol 2002;167:2541-2.
38. Burgdorf W, Orkin M. Granulomatous perivasculitis in Crohn's disease. Arch Dermatol 1981;117:674-75.
39. Slater DN, Waller PC, Reilly G. Cutaneous granulomatous vasculitis: presenting feature of Crohn's disease. J R Soc Med 1985;78:589-90.
40. Lebwohl M, Fleischmajer R, Janowitz H, Present D, Prioleau P. Metastatic Crohn's disease. J Am Acad Dermatol 1984;10:33-8.
41. Perret CM, Bahmer FA. Extensive necrobiosis in metastatic Crohn's disease. Dermatologica 1987;175:208-12.
42. Hackzell-Bradley M, Hedblad MA, Stephannson EA. Metastatic Crohn's disease. Report of 3 cases with special reference to histopathologic findings. Arch Dermatol 1996;132:928-32.
43. Halme L, Meurman JH, Laine P, von Smitten K, Syrjanen S, Lindqvist C, et al. Oral findings in patients with active or inactive Crohn's disease. Oral Surg Oral Med Oral Pathol 1993;76:175-81.
44. Pittock S, Drumm B, Fleming P, McDermott M, Imrie C, Flint S, et al. The oral cavity in Crohn's disease. J Pediatr 2001;138:767-71.
45. Frankel DH, Mostofi RS, Lorincz AL. Oral Crohn's disease: report of two cases in brothers with metallic dysgeusia and a review of the literature. J Am Acad Dermatol 1985;12:260-8.
46. Williams AJ, Wray D, Ferguson A. The clinical entity of orofacial Crohn's disease. Q J Med 1991;79:451-8.
47. Clayton R, Feiwel M. Crohn's disease of the mouth. Proc R Soc Med 1975;68:650-1.
48. Hyams JS. Extraintestinal manifestations of inflammatory bowel disease in children. J Pediatr Gastroenterol Nutr 1994;19:7-21.
49. Scheper HJ, Brand HS. Oral aspects of Crohn's disease. Int Dent J 2002;52:163-72.
50. Berstein ML, McDonald JS. Oral lesions in Crohn's disease: report of two cases and update of the literature. Oral Surg Oral Med Oral Pathol 1978;46:234-45.
51. Ramzan NN, Leighton JA, Heigh RI, Shapiro MS. Clinical significance of granuloma in Crohn's disease. Inflamm Bowel Dis 2002;8:168-73.
52. Barnard KM, Walker-Smith JA. The prevalence of oral manifestations of inflammatory bowel disease in a paediatric population [abstract]. J Dent Res 1994;73:A388.
53. Staines KS, Green R, Felix DH. The management of fistulizing oral Crohn's disease with infliximab. J Oral Pathol Med 2007;36:444-6.
54. rd, Sheridan PJ. Pyostomatitis vegetans as an early sign of reactivation of Crohn's disease: a case report. J Periodontol 2002;73:1512-6.
55. Bogenrieder T, Rogler G, Vogt T, Landthaler M, Stolz W. Orofacial granulomatosis as the initial presentation of Crohn's disease in an adolescent. Dermatology 2003;206:273-8.
56. Gabioud F, Carrel JP, Samson J. Stomatological manifestations of Crohn's disease. Rev Prat 1999;49:1258-60.
57. Quezada S, Turner PL, Alexiev B, Daly B, Cross R. Severe refractory orofacial Crohn's disease: report of a case. Dig Dis Sci 2008; Dec10. (EPub ahead of print)
58. Galbraith SS, Drolet BA, Kugathasan S, Paller AS, Esterly NB. Asymptomatic inflammatory bowel disease presenting with mucocutaneous findings. Pediatrics 2005;116:439-44.
59. Bens G, Laharie D, Beylot-Barry M, Vergier B, Noblesse I, Beylot C, et al. Successful treatment with infliximab and methotrexate of pyostomatitis vegetans associated with Crohn's disease. Br J Dermatol 2003;149:181-4.
60. Dupuy A, Cosnes J, Revuz J, Delchier JC, Gendre JP, Cosnes A. Oral Crohn disease: clinical characteristics and long-term followup of 9 cases. Arch Dermatol 1999;135:439-42.
61. Wiesenfeld D, Ferguson MM, Mitchell DN, Mac Donald DG, Scully C, Cochran K, et al. Oro-facial granulomatosis - a clinical and pathological analysis. Q J Med 1985;54:101-13.
62. Ruocco E, Cuomo A, Salerno R, Ruocco V, Romano M, Baroni A. Crohn's disease and its mucocutaneous involvement (review). Skin Med 2007;694:179-85.
63. Wollina U. Pyoderma gangrenosum - a review. Orphanet J Rare Dis 2007;2:19.
64. Spear M. Pyoderma gangrenosum: an overview. Plast Surg Nurs 2008;28:154-7.
65. Weenig, R, Davis M, Dahl P, Su WP. Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med 2002;347:1412-8.
66. Crowson AN, Mihm MC Jr, Magro C. Pyoderma gangrenosum: a review. J Cutan Pathol 2003;30:97-107.
67. Brooklyn TN, Dunnill MG, Shetty A, Bowden J, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo-controlled trial. Gut 2006;55:505-9.
68. Van den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br Dermatol 1997;137:1000-5.
69. Gregory B, Ho VC. Cutaneous manifestations of gastrointestinal disorders. Part II. J Am Acad Dermatol 1992;26:371-83.
70. Apgar JT. Newer aspects of inflammatory bowel disease and its cutaneous manifestations: a selective review. Semin Dermatol 1991;10:138-47.
71. Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol 2002;3:149-58.
72. Kelly J. Pyoderma gangraenosum: exploring the treatment options. J Wound Care 2001;10:125-8.
73. Mills CC, Amin M, Monisali M. Salivary duct fistula and recurrent buccal space infection: a complication of Crohn's disease. J Oral Maxillofac Surg 2003;61:1485-7.
74. th edn. New York: Mc-Graw Hill; 2008. pp. 1777-89.
75. Cook MG. The size and histological appearance of mesenteric lymph nodes in Crohn's disease.Gut 1972;13:970-2.
76. Pironi L, Cornia GL, Ursitti MA, Dallasta MA, Miniero R, Fasano F, et al. Evaluation of oral administration of folic and folinic acid to prevent folate deficiency in patients with in-flammatory bowel disease treated with salicylazosulfapyridine. Int J Clin Pharmacol Res 1988;8:143-8.
77. Jarrett P, Duffill M, Oakley A, Smith A. Pellagra, azathioprine and inflammatory bowel disease. Clin Exp Dermatol 1997;22:44-5.
78. Oliva MM, Lake AM. Nutritional considerations and management of the child with inflammatory bowel disease. Nutrition 1996;12:151-8.
79. Beattie RM, Croft NM, Fell JM, Afzal NA, Heuschkel RB. Inflammatory bowel disease. Arch Dis Child 2006;91:426-32.
80. O'Keefe SJ. Nutrition and gastrointestinal disease. Scand J Gastroenterol Suppl 1996;220:52-9.
81. Boh EE, al-Smadi RM. Cutaneous manifestations of gastrointestinal diseases. Clin 2002;20:533-46.
82. Timani S, Mutasim DF. Skin manifestations of inflammatory bowel disease. Clin Dermatol 2008;26:265-73.
83. Field EA, Allan RB. Review article: oral ulceration - aetiopathogenesis, clinical diagnosis and management in the gastrointestinal clinic. Aliment Pharmacol Ther 2003;18:949-62.
84. Rehberger A, Puspok A, Stallmeister T, Jurecka W, Wolf K. Crohn's disease masquerading as aphthous ulcers. Eur J Dermatol 1998;8:274-6.
85. Cardoso H, Nunes AC, Carneiro F, Tavarela Veloso F. Successful infliximab therapy for oral Crohn's disease. Inflamm Bowel Dis 2006;12:337-8.
86. Varley EWB. Crohn's disease of the mouth: report of three cases. Oral Surg Oral Med Oral Pathol 1972;33:570-8.
87. Bishop RP, Brewster AC, Antonioli DA. Crohn's disease of the mouth. Gastroenterology 1972;62:302-6.
88. Colella G, Riegler G, Lanza A, Tartaro GP, Russo MI, Tartaglione M. Changes in the mouth mucosa in patients with chronic inflammatory intestinal diseases. Minerva Stomatol 1999;48:367-71.
89. VanHale HM, Rogers RS, Zone JJ, Greipp PP. Pyostomatitis vegetans. A reactive mucosal marker for inflammatory disease of the gut. Arch Dermatol 1985;121:94-8.
90. Hegarty A, Hodgson T, Porter S. Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95:576-85.
91. Present D, Rutgeerts P, Targan B, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
92. Brunner B, Hirschi C, Weimann R, Seibold F. Treatment-resistant lingual Crohn's disease disappears after infliximab. Scand J Gastroenterol 2005;40:1255-9.
93. Miller AM, Elliot PR, Fink R, Connell W. Rapid response of severe refractory metastatic Crohn's disease to infliximab. J Gastroenterol Hepatol 2001;16:940-2.
94. Escher JC, Stoof TJ, van Deventer SJ, Van Furth AM. Successful treatment of metastatic Crohn disease with infliximab. J Pediatr Gastroenterol Nutr 2002;34:420-3.
95. Ginsburg PM, Hanan I, Ehrenpreis ED. Treatment of severe esophageal Crohn's disease with thalidomide. Am J Gastroenerol 2001;96:1305-6.
96. Ginsburg PM, Dassopoulos T, Ehrenpreis ED. Thalidomide for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature. Ann Med 2001;33:516-25.
97. Odeka EB, Miller V. Thalidomide in oral Crohn's disease refractory to conventional medical treatment. J Pediatr Gastroenterol Nutr 1997;25:250-1.
98. Weinstein TA, Sciubba JJ, Levine J. Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease. J Pediatr Gastroenterol Nutr 1999;28:214-6.
99. Sands BE. Medical therapy of steroid-resistant Crohn's disease. Can J Gastroenterol 2000;14 Suppl C:33C-37C.
100. Ricci C, Lanzarotto F, Lanzini A. The multidisciplinary team for management of inflammatory bowel diseases. Dig Liver Dis 2008;40 Suppl 2:S285-8.
101. Sandborn WJ, Hanauer S, Loftus EV Jr, Tremaine WJ, Kane S, Cohen R, et al. An openlabel study of the human anti-TNF monoclonal antibody adalimumab in patients with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004;99:1984-9.
102. Papadakis KA, Shaye OA, Vasiliauskas EA, Ippoliti A, Dubinsky MC, Birt J, et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005;100:75-9.
103. Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med 2000;108:487-95..
104. Jakkula M, Le Cras TD, Gebb S, Hirth KP, Tuder RM, Voelkel NF. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol 2000;279:L600-L607.
105. Lauerma AI,Maibach HI. Topical FK506 - clinical potential or laboratory curiosity? Dermatology 1994;188:173-6.
106. Michel G, Kemény L, Homey B, Ruzicka T. FK506 in the treatment of inflammatory skin disease: promises and perspectives. Immunol Today 1996;17:106-8.
107. Lauerma AI, Surber C, Maibach HI. Absorption of topical tacrolimus (FK506) in vitro through human skin: comparison with cyclosporin A. Skin Pharmacol 1997;10:230-4.
108. Homey B, Assmann T, Vohr HW, Ulrich P, Lauerma AI, Ruzicka T, et al. Topical FK506 suppresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary immune responses. J Immunol 1998;160:5331-40.
109. Murch SH, Walker-Smith JA. Medical management of chronic inflammatory bowel disease. Baillieres Clin Gastroenterol 1994;8:133-48.
110. Mignogna MD, Fortuna G, Leuci S, Massimo A. Oral Crohn's disease: a favorable clinical response with delayed-release triamcinolone acetonide intralesional injections. Am J Gastroenterol 2008;103:2954-5.
111. Casson DH, Eltumi M, Tomlin S, Walker-Smith JA, Murch SH. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut 2000;47:436-40.
112. Estrin HM, Hughes RW Jr. Oral manifestations in Crohn's disease: report of a case. Am J Gastroenterol 1985;80:352-4.
113. Ganesh R, Suresh N, Ezhilarasi S, Rajajee S, Sathiyasekaran M. Crohn's disease presenting as palatal ulcer. Indian J Pediatr 2006;73:229-31.
114. Ficarra G, Cicchi P, Amorosi A, Piluso S. Oral Crohn's disease and pyostomatitis vegetans. An unusual association. Oral Surg Oral Med Oral Pathol 1993;75:220-4.
115. Lim S, Dohil R, Meadows N, Domizio P, Sanderson IR. Treatment of orofacial and ileo-colonic Crohn's disease with total enteral nutrition. J R Soc Med 1998;91:489-90.
116. rd, Sheridan PJ. Oral ulcerations are associated with the loss of response to infliximab in Crohn's disease. J Oral Pathol Med 2005;34:53-5.